Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-Part Study to Evaluate the Safety and Tolerability of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

NCT05795465 is registered in ClinicalTrials.gov with GEn1E Lifesciences as lead sponsor.

NCT NCT05795465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05795465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-Part Study to Evaluate the Safety and Tolerability of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
Lead sponsor
GEn1E Lifesciences
Phase
Phase 2
Overall status
Recruiting
Start date
April 4, 2023
Completion date
December 31, 2026
Enrollment
52 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory distress syndrome, acute